Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 7; no. 1; pp. e12123 - n/a
• Main Authors: Zimmer, Jennifer A., Shcherbinin, Sergey, Devous, Michael D., Bragg, Sonja M., Selzler, Katherine J., Wessels, Alette M., Shering, Craig, Mullen, Jamie, Landry, John, Andersen, Scott W., Downing, AnnCatherine M., Fleisher, Adam S., Svaldi, Diana Otero, Sims, John R.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 2021; John Wiley and Sons Inc; Wiley
• Subjects: Activities of daily living; Alzheimer's disease; amyloid; beta‐site amyloid precursor protein‐cleaving enzyme BACE inhibitor; cerebral metabolism; cerebral perfusion; Cognitive ability; Dementia; Enrollments; florbetapir; flortaucipir; fluorodeoxyglucose; lanabecestat; Magnetic resonance imaging; Medical imaging; Memory; mild cognitive impairment; Neuroimaging; Patients; positron emission tomography; Questionnaires; tau; Tomography; cerebral perfusion; magnetic resonance imaging; tau; fluorodeoxyglucose; flortaucipir; lanabecestat; amyloid; beta‐site amyloid precursor protein‐cleaving enzyme BACE inhibitor; florbetapir; mild cognitive impairment; positron emission tomography; Alzheimer's disease; cerebral metabolism

Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic plaque burden reduction did not result in clinical benefit. Lana...